GLP/GCP: Requirement and implementation (Japan) Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan 1 5 th VICH Outreach.

Slides:



Advertisements
Similar presentations
EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
Advertisements

Introduction to PPDs Regulatory requirements and rationale.
“Reform of the Child Care System: Taking Stock and Accelerating Action” South East Europe 3 – 6 July 2007, Sofia.
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
Good Laboratory Practice (GLP)
Good Laboratory Practices (GLPs)
Good Laboratory Practice
Regulatory Overview.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
1 Regulation of drug research. 2 What is drug research? There are two approaches: a wider and a pragmatic one The latter make a difference between „research.
What is the GLP?.
MB RESEARCH LABORATORIES Increased Regulatory Vigilance with respect to GLP Test Article Characterization George L. DeGeorge, Ph.D., DABT MB Research Laboratories.
Good Laboratory Practice CFR 21 Part 58 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Important informations
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
1 Legislation and Institutional/Administrative Capacities - PLANT PROTECTION - - PLANT PROTECTION - Sub-Committee for Agriculture and Fishery European.
QSR and GLP What exactly are these?.
Overview of FDA's Regulatory Framework for PET Drugs
LEGAL and REGULATORY FRAMEWORK for NUCLEAR and RADIATION SAFETY in BULGARIA General overview Dr. M. Mateeva – Chief Inspector R. Markova-Mihaylova – Chief.
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Overview of Drugs and Biologics Dr Léo Bouthillier, Therapeutic Products Directorate & Dr Omar Tounekti, Biologics and Genetic Therapies Directorate Health.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
VICH General Principles and current update of VICH Outreach Forum activity 1.
Ratification of BWC BWC Expert Group, Republic of Korea Compendium of National Activities in Korea: Measures to Improve Biosafety and Biosecurity Hei Chan.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
TAIEX December 2011 REPUBLIC OF SERBIA Ministry of Agriculture, Trade, Forestry and Water Management VETERINARY DIRECTORATE Animal Health, Welfare.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
* Food Standards Division Korea Food & Drug Administration Guidelines for Establishment of Pesticide and Veterinary Drug MRLs in Food.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.
REPUBLIC OF SERBIA Ministry of Agriculture, Trade Forestry and Water Management VETERINARY DIRECTORATE Department for Anima Health, Welfare and Traceability.
FEDERAL INSTITUTE FOR RISK ASSESSMENT Good Laboratory Practice GLP in practice Dr. Wolf Burchard Bulling Federal Institute for Risk Assessment Thielallee.
GCP (GOOD CLINICAL PRACTISE)
Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.
Responsibilities of Sponsor, Investigator and Monitor
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Registration requirements for vaccines -Strategies to implement VICH GLs- Takashi KOZASA, DVM National Veterinary Assay Laboratory, Ministry of Agriculture,
Good Clinical Practice (GCP) and Monitoring Practices
Issues Batch safety testing for vaccines
GMP IN THE CURRENT REGULATORY EMVIRONMENT
Pharmacovigilance in Korea
Responsibilities of Sponsor, Investigator and Monitor
נמטוציטים משושנת ים Eli. S Lec. No.2.
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
Requirements for GLP and GCP in the EU
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Presentation on Good Manufacturing Practice
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Data Requirements for Old Products/Generics, Bioequivalence
Waiving Target Animal Batch Safety Testing for vaccines
Good Laboratory Practices
Good Laboratory Practice CFR 21 Part 58
The Benefits of VICH to Emerging Countries
Clinical Translation of Stem Cell Therapies: A Bridgeable Gap
VICH Guidelines on stability: OVERVIEW
VICH Guidelines on stability: OVERVIEW
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Control of Veterinary Drugs in South Africa
Storage and distribution
Interconnection of good practices: from development to distribution
Presentation transcript:

GLP/GCP: Requirement and implementation (Japan) Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan 1 5 th VICH Outreach Forum meeting (February 25, 2015)

Legal Cascade for VMPs in Japan Biological products standard National-Assay standard, etc. Regulatory rules specific to VMPs (GLP, GCP, GMP, etc.) Legally-binding Top legislation for medicinal products in Japan Applicable for both MPs and VMPs The Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, etc. MAFF Ministerial Ordinances MAFF Ministerial Announcements from MAFF-HQ Director General or Director from NVAL Director General (including GUIDELINEs) non-binding Notice 2

1. Good Laboratory Practice (GLP) [Article 14(3)] of the Act A person intending to obtain an approval pursuant to Paragraph 1 shall attach documents on the results of clinical studies or any other pertinent data to the application, in accordance with MAFF Ministerial Ordinance.  Ministerial Ordinance on the GLP Standard for the Conduct of Non-Clinical Safety Studies of Veterinary Medical Products (Ordinance No.74 of 1997)  Applied to safety studies, toxicity studies and residue studies on the products intending to use in bovine, equine, swine, chicken, quail, honeybee and aquaculture animals for food  Applied to safety studies and toxicity studies on the products intending to use in dogs and cats 3

Implementation of GLP in Japan  Notice on “Standards for the Conduct of Animal Studies of Veterinary Medical Products” was published in 1987  Applicants were required to submit the dossier with data on safety studies, toxicity studies and residue studies (except companion animals) on the products intending to use in food-producing animals, dogs and cats conducted in accordance with the notice since 1988  MAFF Ministerial Ordinance (GLP Ordinance) was published in 1997 (effective since 1999)  The OECD GLP Working Group confirmed that Japanese GLP of VMPs meets the OECD GLP principle in 2013 after the on-site evaluation visits 4

GLP Ordinance  Purpose (Article 1)  Definitions (Article 2)  Practices for Conduct of Study (Article 3)  Responsibilities of the Sponsor (Article 4) Chapter 1 General Provisions  Personnel (Article 5)  Test Facility Management (Article 6)  Study Director (Article 7)  Quality Assurance Unit (Article 8) Chapter 2 Personnel and Organization 5

GLP Ordinance  Test Facility (Article 9)  Equipment (Article 10) Chapter 3 Test Facility and Equipment  Standard Operating Procedures (Article 11)  Animal Care and Management (Article 12) Chapter 4 Operation at Test Facility 6

GLP Ordinance  Handling Test Items and Reference Items (Article 13)  Reagents and Solutions (Article 14) Chapter 5 Handling of Test Item, etc.  Study Plan (Article 15)  Conduct of the Study (Article 16) Chapter 6 Study Plan and Conduct of Study 7

GLP Ordinance  Final Report (Article 17)  Storage of Study-related Materials (Article 18) Chapter 7 Report and Storage  Compliance matters (Article 19) Chapter 8 Multi-site Study 8

2. Good Clinical Practice (GCP) [Article 14(3)] of the Act A person intending to obtain an approval pursuant to Paragraph 1 shall attach documents on the results of clinical studies or any other pertinent data to the application, in accordance with MAFF Ministerial Ordinance. [Article 80-2] of the Act A person intending to sponsor a clinical trial shall assure that such sponsored trial is conducted in accordance with the standards specified in MAFF Ministerial Ordinance.  Ministerial Ordinance on the GCP Standard for the Conduct of Clinical Studies of Veterinary Medicinal Products (Ordinance No.75 of 1997)  Applied to clinical studies on the products intending to use in bovine, equine, swine, chicken, dogs and cats 9

Implementation of GCP in Japan  Notice concerning “Standards for the Conduct of Clinical Studies of Veterinary Medicinal Products” was published in 1996  MAFF Ministerial Ordinance (GCP Ordinance) was published in 1997 (effective since 1999)  The Ordinance is compliant with VICH GL9 (GCP) implemented in

Thank you for your attention 11